

# Transcriptional Profiling of Macrophages Reveals Distinct Parasite Stage-driven Signatures During Early Infection by *Leishmania Donovanii*

**Visnu Chaparro**

Institut National de la Recherche Scientifique (INRS) – Centre Armand-Frappier Santé Biotechnologie (AFSB)

**Tyson E. Graber**

Children's Hospital of Eastern Ontario Research Institute

**Tommy Alain**

Department of Biochemistry, Microbiology and Immunology, University of Ottawa

**Maritza Jaramillo** (✉ [maritza.jaramillo@inrs.ca](mailto:maritza.jaramillo@inrs.ca))

Institut National de la Recherche Scientifique (INRS) – Centre Armand-Frappier Santé Biotechnologie (AFSB)

---

## Research Article

**Keywords:** mRNA abundance, *Leishmania donovani*, promastigote, amastigote, macrophage, RNAseq

**Posted Date:** October 8th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-944153/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Scientific Reports on April 16th, 2022. See the published version at <https://doi.org/10.1038/s41598-022-10317-6>.

1 **Transcriptional profiling of macrophages reveals distinct parasite stage-driven signatures**  
2 **during early infection by *Leishmania donovani***

3  
4

5 Visnu Chaparro<sup>a</sup>, Tyson E. Graber<sup>b</sup>, Tommy Alain<sup>b,c</sup>, Maritza Jaramillo<sup>a,1</sup>

6

7 <sup>a</sup>Institut National de la Recherche Scientifique (INRS) – Centre Armand-Frappier Santé  
8 Biotechnologie (AFSB), Laval, Quebec, Canada

9 <sup>b</sup>Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada

10 <sup>c</sup>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa,  
11 Ontario, Canada

12

13 <sup>1</sup>Correspondence should be addressed to: [maritza.jaramillo@inrs.ca](mailto:maritza.jaramillo@inrs.ca)

14 INRS – CAFSB, 531 boul. des Prairies, Laval, Québec, H7V 1B7, Canada

15 Tel.: +1 (450) 687-5010 ext. 8872; fax: +1 (450) 686-5566

16

17

18 **Keywords:** mRNA abundance, *Leishmania donovani*, promastigote, amastigote, macrophage,  
19 RNAseq

20

21 **Abstract**

22 Macrophages undergo swift changes in mRNA abundance upon pathogen invasion. Herein we  
23 describe early remodelling of the macrophage transcriptome during infection by amastigotes or  
24 promastigotes of *Leishmania donovani*. Approximately 10% - 16% of host mRNAs were  
25 differentially modulated in *L. donovani*-infected macrophages when compared to uninfected  
26 controls. This response was partially stage-specific as a third of changes in mRNA abundance were  
27 either exclusively driven by one of the parasite forms or significantly different between them. Gene  
28 ontology analyses identified categories associated with immune functions (e.g. antigen  
29 presentation and leukocyte activation) among significantly downregulated mRNAs while  
30 cytoprotective-related categories (e.g. DNA repair and apoptosis inhibition) were enriched in  
31 upregulated transcripts during amastigote infection. Interestingly a combination of upregulated  
32 (e.g. cellular response to IFN $\beta$ ) and repressed (e.g. leukocyte activation, chemotaxis) immune-  
33 related transcripts were overrepresented in the promastigote-infected dataset. In addition,  
34 Ingenuity Pathway Analysis (IPA $\text{\textcircled{R}}$ ) coupled specific mRNA subsets with a number of upstream  
35 transcriptional regulators predicted to be modulated in macrophages infected with *L. donovani*  
36 amastigotes (e.g. STAT1 inhibition) or promastigotes (e.g. NRF2, IRF3, and IRF7 activation).  
37 Overall, our results indicate that early parasite stage-driven transcriptional remodelling in  
38 macrophages contributes to orchestrate both protective and deleterious host cell responses during  
39 *L. donovani* infection.

40

## 41 **Introduction**

42 Macrophages are the main replicative niche of protozoan parasites of the genus *Leishmania*, the  
43 etiologic agents of a spectrum of vector-borne diseases known as leishmaniases<sup>1</sup>. Within  
44 macrophages, sandfly-transmitted *Leishmania* promastigotes transform into amastigotes while  
45 subverting numerous host cell processes and immunological functions to ensure its proliferation<sup>1</sup>.  
46 Visceral leishmaniasis (VL) is a life-threatening disease that is caused by *L. donovani* and *L.*  
47 *infantum* (syn. *L. chagasi*)<sup>2</sup>. VL is endemic in more than 60 countries where it represents a severe  
48 public health concern due to the lack of vaccines and the emergence of parasite drug resistance<sup>3</sup>.  
49 Hence, a better understanding of the molecular events occurring at the host cell–parasite interface  
50 is critical to target novel regulatory nodes for therapeutic intervention.

51  
52 Early remodelling of the transcriptome has been reported in macrophages during bacterial and  
53 parasitic infections<sup>4-7</sup>. Even though *Leishmania* promastigotes elicit the activation of anti-parasitic  
54 intracellular signals in macrophages as early as 15 min post-infection (p.i.) (e.g. MAPK p38  
55 phosphorylation)<sup>8</sup>, they are able to dampen host cell responses involved in pathogen clearance  
56 within 2 - 6 h.p.i. (e.g. phagolysosome maturation, antigen presentation, oxidative burst, and  
57 apoptosis)<sup>1,9-11</sup>. Consistent with this, rapid modulation of multiple transcription factors (e.g.  
58 STAT1, NRF2, IRF3 and IRF7) has been associated with either parasite persistence or host cell  
59 defense mechanisms against *L. donovani*<sup>12-15</sup>. Surprisingly, global-scale transcriptional profiling  
60 of *L. donovani*-infected macrophages has only been documented at  $\geq 12$  h.p.i.<sup>16-20</sup>. Therefore,  
61 currently available datasets may not reflect the totality of changes in gene expression programs  
62 that trigger, or are elicited by, early macrophage responses during *L. donovani* infection. Of note,  
63 to the best of our knowledge, no high throughput study comparing early transcriptional changes in

64 macrophages driven by both stages of *L. donovani* is available to date. Herein, using *L. donovani*  
65 amastigote- and promastigote-infected RNA sequencing (RNAseq) datasets, we describe broad  
66 and selective changes in the transcriptome of *L. donovani*-infected macrophages that are likely to  
67 tailor key cellular responses involved in host defense but also in disease progression during VL.  
68

## 69 **Results**

### 70 **Infection with *L. donovani* amastigotes or promastigotes promotes early changes in the** 71 **mRNA pool of the host cell**

72 To compare the early effects of the two life stages *L. donovani* in the mature mRNA pool of the  
73 host cell, total cytosolic mRNA extracts from bone marrow-derived macrophage (BMDM)  
74 cultures infected with amastigote (AMA) or promastigote (PRO) parasites for 6 h were subjected  
75 to RNAseq and compared to non-infected controls (CTR) (**Fig 1A**). As shown by a projection of  
76 a principal component analysis, infection appears to be the main source of variation (37.4%)  
77 between the different datasets followed by a distinctive profile of the AMA-infected samples (**Fig**  
78 **1B**). Differentially regulated mRNAs were identified using the *anota2seq* algorithm with a false  
79 discovery rate (FDR)  $\leq 0.05$  and a  $\log_2$  expression fold-change  $\geq 1.0$ . Out of 9442 mRNAs detected  
80 in BMDMs, 9.9% showed differential abundance during *L. donovani* amastigote infection (65.6%  
81 upregulated and 34.4% downregulated) (**Fig 1C** left panel and **Table S1**) while 15.8% were altered  
82 in BMDMs following infection with the promastigote stage (54.4% upregulated and 45.6%  
83 downregulated) (**Fig 1C** right panel and **Table S1**). These data indicate that infection by either  
84 amastigotes or promastigotes of *L. donovani* leads to early reprogramming of the mRNA content of  
85 the host cell.

86

### 87 ***L. donovani* amastigote infection modulates the abundance of mRNAs linked to different** 88 **macrophage cellular processes**

89 Gene Ontology (GO) hierarchical clustering analysis was carried out to determine whether subsets  
90 of mRNAs encoding functionally related proteins are selectively modulated in BMDMs upon  
91 infection with *L. donovani* amastigotes (**Fig 2A** and **Table S2**). Enrichment of functional

92 categories related to regulation of gene expression, positive regulation of DNA repair, and negative  
93 regulation of apoptosis and protein modification was detected in the AMA-upregulated dataset  
94 (**Fig 2A** upper panel, and **Table S2**). Targets in these categories included transcripts that encode  
95 transcription (*Bdp1, Gtf3c6, Polr3f, Polr3g*), splicing (*Hnrnpa3, Hnrnpu, Sf3a2, Srsf1*) and  
96 translation (*Dhx29, Eif1a, Eif3a, Eif4g2*) factors, proteins involved in DNA repair (*Lig4, Mdc1,*  
97 *Smc6, Topbp1*), and inhibitors of apoptosis (*Bcl2, Hdac2, Hsph1, Mdm2*) (**Fig 2B**). In contrast,  
98 categories associated with immune response, cell adhesion, signal transduction, protein refolding,  
99 and cell cycle were enriched in the AMA-downregulated dataset (**Fig 2A** bottom panel and **Table**  
100 **S2**). Accordingly, lower levels of transcripts encoding innate and adaptive immune mediators  
101 (*Aif1, C1rb, Ccl5, Ifitm3, Il18bp, Irf7, Ly86, Lyz1, Nfil3, Ptger3, Tnfrsf14*), regulators of antigen  
102 presentation (*Cd74, H2-Aa, H2-Ab1, H2-Eb1, Unc93b1*), and adhesion molecules (*Icam1, Itgal,*  
103 *Itgb7, Rac2*) were detected in BMDMs infected with *L. donovani* amastigotes (**Fig 2B**).

104

### 105 **Functional groups of transcripts are modulated in macrophages upon *L. donovani*** 106 **promastigote infection**

107 Enriched GO categories in upregulated transcripts of *L. donovani* promastigote-infected  
108 macrophages revealed contrasting groups of activating (i.e. *Cxcl10, Cxcl3, Gbp3, Ifit1, Ifit2,*  
109 *Irgm1, Tnf*) and inhibitory immune factors (*Cd200, Cd24a, Cd274, Cebpb, Nlrc5, Serpinb9, Socs1*)  
110 (**Fig 3A** upper panel, **Fig 3B** and **Table S2**). In parallel, mRNAs encoding proteins associated with  
111 cell survival (*Hmox1, Hsp90ab1, Optn, Wfs1*), iron transport (*Slc11a2, Slc25a37, Slc39a14,*  
112 *Slc40a1*) and redox homeostasis (*Cat, Gclm, Gsr, Prdx1, Sod2, Txnrd1*) were also overrepresented  
113 in the upregulated dataset (**Fig 3A** upper panel, **Fig 3B** and **Table S2**). In contrast, GO categories  
114 related to cell death (*Casp2, Casp6, Cradd, Dfna5, Dusp6, Mef2c, Rassf2, Sarm1*) and immune

115 functions such as leukocyte activation (*Clec4a2*, *Dock8*, *Gpr183*, *Hdac5*, *Ifngr1*, *Notch1*),  
116 chemotaxis (*Ccr2*, *Cx3cr1*, *Cxcl14*, *Cxcr3*), and antigen presentation (*Fcgr3*, *H2-DMA*, *H2-DMb1*,  
117 *H2-DMb2*) were enriched in mRNAs with reduced abundance during infection by *L. donovani*  
118 promastigotes (**Fig 3A** lower panel, **Fig 3B** and **Table S2**).

119

## 120 **Parasite stage-specific modulation of the host cell transcriptome during *L. donovani* infection**

121 *Anota2seq* identified a subset of mRNAs (n=649) differentially regulated in the PRO- versus  
122 AMA-infected datasets (52.2% upregulated and 47.8% downregulated) (**Fig 4A** and **Table S1**).

123 Comparison of this subset of transcripts with the AMA vs CTRL and PRO vs CTRL contrasts  
124 shown in **Fig. 1C** (**Table S1**) revealed a complex pattern of regulation with targets exhibiting a

125 stage-exclusive (i.e. PRO only, AMA only), stage-enhanced (i.e. PRO enhanced, AMA enhanced)

126 and stage-opposite (i.e. UP by PRO and DOWN by AMA, DOWN by PRO and UP by AMA)

127 effects (**Figs 4B-C** and **Table S1**). In the upregulated PRO versus AMA dataset (n=339),

128 *anota2seq* classified 70% of the transcripts as PRO only UP, 17% as AMA only DOWN, and 11%

129 as PRO enhanced UP (i.e. UP by PRO and AMA but with a stronger effect in PRO) (**Fig 4B** and

130 **Table S1**). In the downregulated PRO versus AMA dataset (n=310), *anota2seq* classified 69% of

131 the transcripts as PRO only DOWN, 23% as AMA only UP, and 6% as PRO enhanced DOWN

132 (i.e. DOWN by PRO and AMA but with a stronger effect in PRO) (**Fig 4B** and **Table S1**). In

133 addition, 7 transcripts showed an enhanced effect by amastigotes (i.e. AMA enhanced, 3 UP and

134 4 DOWN) (**Fig 4B**, **Fig 4C**, right panel, and **Table S1**) whereas 7 transcripts were oppositely

135 regulated between both stages, including 3 that were classified as PRO UP and AMA DOWN

136 (*Acss2*, *Slc16a3*, *Slpi*), and 4 as PRO DOWN and AMA UP (*Bcr*, *Fcrls*, *Gcnt1*, *Id1*) (**Fig 4B**, **Fig**

137 **4C**, right panel, and **Table S1**).

138 Hierarchical clustering of transcripts identified as exclusively regulated upon amastigote infection  
139 (i.e. AMA only) revealed an enrichment of GO categories among upregulated transcripts encoding  
140 proteins associated with Immune signaling (*Cad*, *Ccl2*, *Wnk1*), DNA repair (*Mcm2*, *Nucks1*,  
141 *Pds5v*, *Rif1*, *Smc2*), and Transcription (*Etv1*, *Etv5*, *Myc*, *Rbl1*, *Sox4*), and Cell adhesion (*Icam1*,  
142 *Slfm1*) (**Fig 4C**, left panel, and **Table S2**) while downregulated targets exhibited an enrichment of  
143 GO categories associated with Immune response (*Ccl5*, *Cd14*, *H2-Aa*, *H2-Ab1*, *H2-Eb1*, *Il18bp*,  
144 *Irf7*, *Ly6c1*, *Ly6c2*, *Nfil3*) and Redox balance (*Folr1*, *Mgst1*, *Ppard*) (**Fig 4C**, left panel, and **Table**  
145 **S2**). The same type of analysis in the dataset of exclusively upregulated mRNAs upon  
146 promastigote infection (i.e. PRO only UP) identified GO categories related to Apoptosis regulation  
147 (i.e. *Cd274*, *Gclm*, *Optn*), Hydrogen peroxide metabolism (*Cat*, *Prdx1*, *Prdx6*, *Txnrd1*), Response  
148 to protozoan (*Cd40*, *Gbp2*, *Gbp3*, *Slc11a1*), and Response to type I IFN (*Ifit1*, *Ifit2*, *Igtp*, *Irgm1*,  
149 *Mnda*) (**Fig 4C**, middle panel, and **Table S2**). By contrast, transcripts exclusively downregulated  
150 by promastigotes (i.e. PRO only DOWN) were enriched in GO categories linked to Cell activation  
151 (*Ajuba*, *Gpr183*, *Hdac5*, *Tcf4*), Chemotaxis (*Arap3*, *Dab2*, *Dock1*, *Itga6*) and Cell signaling  
152 (*Btd11*, *Nfatc2*, *Pak1*, *Pram1*) (**Fig 4C**, middle panel, and **Table S2**). The PRO enhanced UP  
153 subset showed an overrepresentation of apoptosis inhibitors (*Bcl2a1d*, *Gbe1*, *Gclc*, *Hmox1*, *Il1rn*,  
154 *Plk2*, *Serpinb9*) (**Fig 4C**, right panel, and **Table S2**) whereas no GO categories were enriched in  
155 the amastigote enhanced subset. Altogether, these results indicate that early infection by  
156 amastigotes or promastigotes of *L. donovani* elicits a selective and stage-specific transcriptional  
157 signature in macrophages involving mRNAs related to key cellular functions in disease  
158 progression.

159

160 **Changes in host mRNA abundance upon *L. donovani* infection are associated with a network**  
161 **of upstream transcriptional regulators in macrophages**

162 In order to identify potential upstream regulatory networks responsible for the changes in mRNA  
163 levels observed in BMDMs infected by the two life stages of *L. donovani*, we used Ingenuity®  
164 Pathway Analysis (IPA®). With an activation score  $|Z| \geq 2.0$  and an FDR  $\leq 0.01$ , IPA® identified  
165 subsets of transcripts with a regulatory trend predicted to be dependent on the activation or  
166 inhibition of different transcriptional modulators in BMDMs infected with *L. donovani*  
167 amastigotes or promastigotes (**Table S3**). Some upstream regulators were common between both  
168 parasite stages (MYC, KLF4, and SMAD3) albeit with variations in the number and/or identity of  
169 downstream targets in each type of infection (**Fig 5A** left panel and **S3 Table**). Others were  
170 predicted to be activated only by amastigotes (YY1, WDR5, and TP73) or promastigotes  
171 (NFE2L2, IRF7, IRF3, EPAS1, SPI1, NFATC2, ATF4, IFI16, CEBPB, CREB1, SP1, FOXO1,  
172 and FOS) (**Fig 5A** left panel and **Table S3**) while another group was predicted to be inhibited only  
173 upon infection with amastigotes (SOX6, RUNX3, and STAT1) or promastigotes (TRIM24 and  
174 FOXP3) (**Fig 5A** right panel and **Table S3**). Of note, Sirtuin 1 (SIRT1) was predicted to be  
175 activated in the amastigote-infected dataset whereas the opposite was found in the promastigote-  
176 infected dataset (**Fig 5A** and **Table S3**). As expected, transcriptional regulators predicted to be  
177 activated upon *L. donovani* infection showed high percentages of associated upregulated mRNAs  
178 (**Fig 5B**). These data hint at the involvement of a complex regulatory network affecting the  
179 abundance of functional subsets of mRNAs in BMDMs infected with *L. donovani* amastigotes or  
180 promastigotes.

181

## 182 **Discussion**

183 Accumulating evidence indicates that modulation of transcriptional profiles in infected  
184 macrophages is pathogen-specific<sup>21</sup>. Transcriptome-wide analyses of macrophages infected with  
185 *L. donovani* have been described at  $\geq 12$  h.p.i.<sup>16-20,22</sup>, thereby omitting an earlier timeframe during  
186 which numerous molecular and cellular changes occurring within infected macrophages<sup>8-10,23</sup>  
187 could trigger, or be elicited by, selective reprogramming of the host transcriptome. Herein, using  
188 RNAseq, we describe rapid changes in the levels of mRNAs of primary murine macrophages  
189 infected with *L. donovani* amastigotes and promastigotes. Distinct transcriptional signatures were  
190 identified in macrophages infected with each parasite stage. A marked inhibition of mRNAs  
191 encoding proteins related to different immune functions was found in the amastigote-infected  
192 dataset whereas a combination of activating and inhibitory immune modulators was observed in  
193 promastigote-infected macrophages. Additionally, our *in silico* analyses identified host mRNA  
194 signatures in the up- and downregulated datasets that appear to be under the control of parasite-  
195 stage driven networks of transcription factors. These observations indicate that amastigotes and  
196 promastigotes of *L. donovani* elicit a complex transcriptome-wide reprogramming in infected  
197 macrophages that includes both parasite stage-specific and commonly regulated mRNA subsets.

198

199 *L. donovani* amastigote-driven changes in macrophage gene expression have been documented at  
200  $\geq 24$  h.p.i.<sup>17,18,24</sup>. Herein, we provide evidence that *L. donovani* amastigote infection leads to a vast  
201 remodelling of the macrophage transcriptome as early as 6 h.p.i. Among the downregulated targets,  
202 we found an enrichment in mRNAs encoding proteins related to several macrophage immune  
203 functions. IPA® predicted that some of these changes are dependent on the inhibition of

204 transcription factor STAT1. In this regard, Matte and Descoteaux previously reported that *L.*  
205 *donovani* amastigotes prevent STAT1 nuclear import and pro-inflammatory gene expression (i.e.  
206 *Nos2* and *Ifr1*) in BMDMs stimulated with IFN $\gamma$ <sup>12</sup>. In addition, a transcriptomic study carried out  
207 in splenic macrophages revealed that these cells become insensitive to IFN $\gamma$  during experimental  
208 VL despite a strong pro-inflammatory environment in the spleen<sup>18</sup>. Hence, it is plausible that early  
209 blockade of STAT1-dependent transcriptional programs in macrophages infected by *L. donovani*  
210 amastigotes has a negative effect in IFN $\gamma$ -mediated microbicidal and immune host responses at  
211 later stages of the disease. Further investigation is required to shed light on this matter.

212

213 Infection of macrophages results in an oxidative burst response that involves the production of  
214 potent microbicidal effectors such as reactive oxygen and nitrogen species<sup>25</sup>. However, the  
215 antimicrobial oxidative stress response can also compromise macrophage DNA integrity and lead  
216 to the activation of apoptotic signals<sup>26</sup>. Our GO analyses showed an enrichment in mRNAs  
217 encoding DNA repair enzymes and inhibitors of apoptosis in the upregulated dataset of *L.*  
218 *donovani* amastigote-infected BMDMs at 6 h.p.i. Similarly, a proteome-based analysis of human  
219 macrophages infected with *L. donovani* identified DNA repair as an enriched ontology category  
220 reaching maximal values at 24 h.p.i.<sup>27</sup>. Moreover, among *L. donovani* promastigote- and  
221 amastigote-upregulated transcripts, we detected *Nbn*, which encodes a key member of the MRE11  
222 DNA-damage-sensing complex<sup>28</sup>. Interestingly, *Nbn* is also induced in macrophages upon LPS-  
223 induced oxidative damage and serves as a modulator of macrophage homeostasis preventing  
224 attrition<sup>29</sup>. These reports along with our RNAseq data indicate *L. donovani* amastigotes elicit a  
225 cytoprotective transcriptional program to prevent oxidative-driven macrophage apoptosis at early  
226 stages of infection. Future studies are necessary to fully understand the molecular underpinnings

227 of parasite-driven activation of the host DNA repair machinery and its role in the establishment  
228 and progression of *L. donovani* infection within macrophages.

229

230 *Leishmania* parasites inhibit macrophage oxidative burst in order to survive<sup>1</sup>. Recently, Reverte *et*  
231 *al.* showed that expression of the transcription factor NRF2, a master regulator of the antioxidant  
232 response<sup>30</sup>, is augmented during *Leishmania* spp. infection, including *L. donovani*<sup>11</sup>. Furthermore,  
233 upregulation of NRF2 activity contributed to promote parasite persistence during *L. guyanensis*  
234 infection by limiting inflammation<sup>11</sup>. In addition, NRF2-dependent increase in heme oxygenase 1  
235 (HO-1) and ATF3 upon *L. donovani* infection was critical in dampening macrophage oxidative  
236 burst and proinflammatory cytokine expression as part of a parasite survival strategy<sup>15</sup>. Thus, our  
237 data showing an enrichment of transcripts associated with the activation of an NRF2-dependent  
238 antioxidant response (*Hmox1*, *Nqo1*, *Gsta3*, *Gstm1*) in promastigote-infected BMDMs suggest that  
239 targeting this regulatory node could be a therapeutic approach to combat VL.

240

241 In line with subversion of macrophage immune functions by *L. donovani* promastigotes<sup>1</sup>, we  
242 identified a number of mRNAs encoding immune inhibitors in the upregulated promastigote-  
243 infected dataset, including *Cd274* (a.k.a. PDL1), *Socs1*, and *Cd200*. PDL1 and its receptor PD1  
244 constitute an important inhibitory axis for T cell activity, and antibody therapy against PD1 has  
245 proven successful against numerous malignancies<sup>31</sup>. Notably, the PD1/PDL1 axis was recently  
246 identified to play an important role *in vivo* during VL and immunotherapy against PD1 was  
247 effective in hampering parasite burden and pathogenesis<sup>22</sup>. In addition, early induction of SOCS1,  
248 a known antagonist of the proinflammatory JAK1/STAT1 pathway<sup>29,32</sup>, was identified as part of a

249 cellular program to prevent oxidative burst-mediated apoptosis in macrophages infected with *L.*  
250 *donovani*<sup>33</sup>. Similarly, a swift increase of CD200 in macrophages exposed to *L. amazonensis* or *L.*  
251 *donovani* infection was described as a strategy to favor parasite proliferation<sup>34-36</sup>. Interestingly,  
252 immune blockade of CD200 led to an increase in proinflammatory mediators and parasite  
253 elimination capacity of macrophages and T cells, showing its potential as a therapeutic target<sup>36</sup>.  
254 Taken together, these reports and our transcriptomic study highlight the early ability of *L. donovani*  
255 promastigotes to limit macrophage antimicrobial responses through the modulation of host mRNA  
256 abundance.

257

258 IPA® identified a transcriptional signature associated with type I interferon responses predicted to  
259 be activated via the transcription factors IRF3 and IRF7 in the promastigote-upregulated dataset.  
260 By contrast, downregulation of *Irf7* mRNA abundance was detected in the transcriptome of  
261 amastigote-infected BMDMs. IRF7-dependent parasite elimination was reported in macrophages  
262 of the splenic marginal zone during the acute phase of *L. donovani* amastigote infection *in vivo*  
263 (e.g. 5 to 48 h.p.i.) and by a cell line of stromal macrophages *in vitro*. Although the expression of  
264 IRF7 was not modulated in hepatic macrophages during VL, IRF7-deficient mice showed a  
265 decreased ability to control parasite burden in the liver<sup>37</sup>. These observations along with  
266 transcriptomic data and our *in silico* analysis suggest that the ability of macrophages to elicit  
267 IRF7-dependent antimicrobial transcriptional programs upon *L. donovani* infection is tissue-  
268 and/or parasite-stage specific.

269

270 Our group recently described rapid remodeling of the translome of macrophages infected by  
271 promastigotes and amastigotes of *L. donovani*<sup>38</sup>. Herein, we expanded our findings by analysing  
272 early changes in the abundance of host mRNAs during infection. Comparison of the transcriptome  
273 and the translome of *L. donovani*-infected BMDMs at 6 h.p.i. indicates that in contrast to changes  
274 in translation efficiency<sup>38</sup>, modulation of mRNA abundance is, at least in part, parasite stage-  
275 specific. Amastigote-driven changes included the upregulation of transcripts encoding for DNA  
276 repair modulators while inhibiting those encoding for antigen-presenting and macrophage  
277 activation factors. Alternatively, promastigote-infected macrophages showed the upregulation of  
278 immune inhibitors as well as an antioxidant transcriptional signature associated to NRF2 activity.  
279 However, enrichment of transcripts associated with IRF3 and IRF7 suggests that macrophages are  
280 able to activate antimicrobial pathways upon *L. donovani* promastigote infection. Interestingly,  
281 mRNAs encoding proteins associated with DNA damage-sensing or DNA repair, apoptosis  
282 inhibition and mRNA metabolism were upregulated via changes in abundance (**Figs 2 - 4**) and  
283 translation efficiency<sup>38</sup>. A similar dual effect was observed on a number of downregulated  
284 immune-related transcripts (e.g. antigen presentation, leukocyte activation, etc.)<sup>38</sup> (**Figs 2 - 4**). In  
285 all, previous studies, along with our current findings support the notion that early parasite-driven  
286 changes in macrophage gene expression programs are under the control of transcriptional and post-  
287 transcriptional regulatory mechanisms that tailor both protective and harmful host cell responses  
288 during *L. donovani* infection.

289

## 290 **Materials and Methods**

### 291 **Reagents and Parasites**

292 Culture media and supplements were purchased from Wisent, Gibco, and Sigma-Aldrich. *L.*  
293 *donovani* (LV9 strain) amastigotes were isolated from the spleen of infected female Golden Syrian  
294 hamsters (Harlan Laboratories) as previously described<sup>12</sup>. *L. donovani* (LV9 strain) promastigotes  
295 were differentiated from freshly isolated amastigotes and were cultured at 26°C in M199 medium  
296 supplemented with FBS (10%), hypoxanthine (100 µM), hemin (5 µM), biopterin (3 µM), biotin  
297 (1 µM), penicillin (100 U/mL), and streptomycin (100 µg/mL). Early passage stationary phase  
298 promastigotes were used for macrophage infections.

299

### 300 **Ethics Statement**

301 Housing and experiments were carried out under protocols approved by the Comité Institutionnel  
302 de Protection des Animaux (CIPA) of the INRS – Centre Armand-Frappier Santé Biotechnologie  
303 (CIPA 1308-04 and 1710-02). All methods were performed in accordance with relevant guidelines  
304 and regulations. These protocols respect procedures on good animal practice provided by the  
305 Canadian Council on animal care. The study is reported in accordance with ARRIVE guidelines.

306

### 307 **Differentiation and infection of bone marrow-derived macrophages**

308 Bone marrow-derived macrophages (BMDMs) were generated from precursor cells from murine  
309 bone marrow, as previously described<sup>39</sup>. Briefly, marrow was extracted from bones of the hind  
310 legs, red blood cells were lysed, and progenitor cells were resuspended in BMDM culture medium  
311 supplemented with 15% L929 fibroblast-conditioned culture medium (LCCM). Non-adherent cells  
312 were collected the following day and were cultured for 7 days in BMDM culture medium

313 supplemented with 30% LCCM with fresh medium replenishment at day 3 of incubation. BMDM  
314 cultures were inoculated with *L. donovani* promastigotes or amastigotes at a multiplicity of  
315 infection (MOI) of 10:1 for 6 h, as previously described<sup>40</sup>. Prior to infection, cells were serum-  
316 starved for 2 h.

317

### 318 **Cytosolic mRNA extraction**

319 Cytosolic lysates of infected and control BMDMs were prepared for RNA extraction as  
320 described<sup>39</sup>. RNA was extracted with QIAzol (Qiagen) and purified using RNeasy MinElute  
321 Cleanup Kit (Qiagen) according to specifications of the manufacturer. Purity and integrity of RNA  
322 was assessed using a Bioanalyzer 2100 with a Eukaryote Total RNA Nano chip (Agilent  
323 Technologies).

324

### 325 **RNAseq and data processing**

326 RNAseq libraries were generated using the Smart-seq2 method<sup>41</sup> and sequenced by using an  
327 Illumina HiSeq2500 instrument with a single-end 51-base sequencing setup from three  
328 independent biological replicates for uninfected and *L. donovani* promastigote-infected BMDMs,  
329 and five independent biological replicates for *L. donovani* amastigote-infected BMDMs. First,  
330 RNAseq reads mapping to the reference genome of the Nepalese BPK282A1 strain of *L. donovani*  
331 (txid: 981087) were removed (12.7% and 1.4% mappings on average for promastigotes and  
332 amastigotes, respectively). The filtered reads were then mapped to the mouse genome assembly  
333 GRCm38 (mm10) using HISAT2 with default settings<sup>42</sup>. Gene expression was quantified using  
334 the RPKMforgenes.py script<sup>41</sup> with -fulltranscript -readcount -onlycoding flags from which raw

335 per-gene RNAseq counts were obtained (version last modified 07.02.2014). Genes that had zero  
336 counts in all samples were discarded. Annotation of genes was obtained from RefSeq.

### 337 **RNAseq data analysis using *anota2seq***

338 RNAseq counts were normalized within *anota2seq* using the default TMM-log2 method<sup>43</sup>.  
339 Significant changes in mRNA abundance were identified by *anota2seq*<sup>43</sup> using the default  
340 parameters with the following modifications: FDR  $\leq 0.05$ ; *apvEff*  $> \log_2(2.0)$ . In *anota2seq*, the  
341 number of contrasts per analysis equals  $n-1$  being  $n$  the number of conditions (i.e. CTR, *Ld* AMA,  
342 *Ld* PRO). In analysis one, infections were contrasted to the uninfected control (i.e. *Ld* PRO versus  
343 CTR and *Ld* AMA versus CTR); in analysis two, cells infected by different parasite stages were  
344 compared together and an additional contrast was included to complete the *anota2seq* parameters  
345 (i.e. *Ld* PRO vs *Ld* AMA and *Ld* PRO versus CTR). Identifiers for genes which cannot be  
346 distinguished based on their high sequence similarity (also reported by RPKMforgenes.py), were  
347 excluded from downstream analyses.

348

### 349 **Gene ontology analyses**

350 Gene ontology analyses were performed using the PANTHER<sup>TM</sup> tool<sup>44</sup> of the Gene Ontology  
351 Consortium (<http://geneontology.org/>) on the union of transcripts activated or inhibited in BMDMs  
352 infected by *L. donovani* amastigotes or promastigotes. Heatmaps of abundance of transcripts  
353 activated or inhibited in BMDMs infected by *L. donovani* amastigotes or promastigotes were  
354 generated using Morpheus.

355 (<https://software.broadinstitute.org/morpheus/index.html>, Broad Institute)

356

### 357 **Ingenuity® Pathway Analysis**

358 Enrichment of transcripts showing differential abundance in specific functional networks was  
359 determined using Ingenuity® Pathway Analysis (IPA®; Qiagen) by comparing *anota2seq*-  
360 regulated gene sets against the entire sequenced datasets<sup>45</sup>. Within the IPA® application, statistical  
361 significance was calculated using a right-tailed Fisher Exact test and p-values were adjusted for  
362 multiple hypothesis testing using the Benjamini-Hochberg method to arrive at a FDR.

363 **Figure Captions**

364 **Figure 1. *L. donovani* infection leads to transcriptome-wide changes in macrophage mRNA**  
365 **abundance.** (A) Strategy to identify cytosolic mRNAs that are regulated in *L. donovani* amastigote  
366 (AMA)- or promastigote (PRO)-infected BMDMs. RNAseq experiments were carried out in three  
367 to five biological replicates per condition. (B) Cytosolic mRNA datasets of BMDMs infected or  
368 not with *L. donovani* AMA or PRO were projected on the first two components of a principal  
369 component analysis. (C) Scatter plots of gene expression as RPKM ( $\log_2$ ) values for total cytosolic  
370 mRNA. Differentially regulated transcripts are indicated in red (Upregulated) or blue  
371 (downregulated). Unchanged mRNAs are shown in grey.

372

373 **Figure 2. Selective changes in mRNA abundance predict amastigote-specific modulation of**  
374 **key biological processes in macrophages during *L. donovani* infection.** (A) FDR values ( $-\log_{10}$ )  
375 for selected GO term enriched categories of differentially up- or downregulated mRNAs upon *L.*  
376 *donovani* AMA infection. (B) Changes in mRNA abundance for selected genes in enriched GO  
377 terms. Analyses were carried out on data generated from at least three biological replicates.

378

379 **Figure 3. Selective changes in mRNA abundance predict promastigote-specific modulation**  
380 **of key biological processes in macrophages during *L. donovani* infection.** (A) FDR values ( $-\log_{10}$ )  
381 for selected GO term enriched categories of differentially up- or downregulated mRNAs  
382 upon *L. donovani* PRO infection. (B) Changes in mRNA abundance for selected genes in enriched  
383 GO terms. Analyses were carried out on data generated from at least three biological replicates.

384

385 **Figure 4. Parasite stage-driven changes in macrophage mRNA abundance during *L.***  
386 ***donovani* infection.** (A) Scatter plot of gene expression as RPKM (log<sub>2</sub>) values for total mRNA  
387 between PRO and AMA datasets. Differentially regulated transcripts are indicated in red  
388 (Upregulated) or blue (downregulated). Unchanged mRNAs are shown in grey. (B) Category  
389 distribution of transcripts differentially regulated in macrophages upon *L. donovani* PRO versus  
390 AMA infection. (C) Heatmaps of selected transcripts differentially regulated only by amastigotes  
391 (left panel), promastigotes (center panel) or both (right panel). Manually curated ontology groups  
392 are shown for stage-specific regulated transcripts (left and middle panels). Analyses were carried  
393 out on data generated from at least three biological replicates.

394

395 **Figure 5. Ingenuity® Pathway Analysis predicts parasite stage-specific modulation of**  
396 **transcriptional regulators in macrophages infected *L. donovani*.** (A) Activation score (Z) of  
397 transcriptional regulators predicted to be involved in the changes of mRNA abundance in  
398 macrophages upon *L. donovani* AMA and PRO infection. \*Common upstream regulators  
399 identified in PRO, AMA datasets by IPA®. (B) Percentage distribution of upregulated mRNAs  
400 associated with upstream transcriptional regulators predicted to be activated in macrophages upon  
401 *L. donovani* AMA and PRO infection. Total number of genes regulated by each transcription factor  
402 are shown in brackets. Analyses were carried out on data generated from at least three biological  
403 replicates.

404

405

406 **References**

- 407 1 Podinovskaia, M. & Descoteaux, A. Leishmania and the macrophage: a multifaceted  
408 interaction. *Future microbiology* **10**, 111-129, doi:10.2217/fmb.14.103 (2015).
- 409 2 Khadem, F. & Uzonna, J. E. Immunity to visceral leishmaniasis: implications for  
410 immunotherapy. *Future Microbiology* **9**, 901-915, doi:10.2217/fmb.14.43 (2014).
- 411 3 Burza, S., Croft, S. L. & Boelaert, M. Leishmaniasis. *Lancet* **392**, 951-970,  
412 doi:10.1016/S0140-6736(18)31204-2 (2018).
- 413 4 Bhatt, D. M. *et al.* Transcript dynamics of proinflammatory genes revealed by sequence  
414 analysis of subcellular RNA fractions. *Cell* **150**, 279-290, doi:10.1016/j.cell.2012.05.043  
415 (2012).
- 416 5 Goldmann, O. *et al.* Transcriptome analysis of murine macrophages in response to  
417 infection with *Streptococcus pyogenes* reveals an unusual activation program. *Infection*  
418 *and immunity* **75**, 4148-4157, doi:10.1128/IAI.00181-07 (2007).
- 419 6 Li, Y. *et al.* Transcriptome Remodeling in *Trypanosoma cruzi* and Human Cells during  
420 Intracellular Infection. *PLoS Pathogens* **12**, e1005511, doi:10.1371/journal.ppat.1005511  
421 (2016).
- 422 7 Rabhi, S. *et al.* Lipid Droplet Formation, Their Localization and Dynamics during  
423 *Leishmania major* Macrophage Infection. *PloS One* **11**, e0148640,  
424 doi:10.1371/journal.pone.0148640 (2016).
- 425 8 Junghee, M. & Raynes, J. G. Activation of p38 mitogen-activated protein kinase attenuates  
426 *Leishmania donovani* infection in macrophages. *Infection and immunity* **70**, 5026-5035,  
427 doi:10.1128/IAI.70.9.5026-5035.2002 (2002).

- 428 9 Giri, J. *et al.* Leishmania donovani Exploits Myeloid Cell Leukemia 1 (MCL-1) Protein to  
429 Prevent Mitochondria-dependent Host Cell Apoptosis. *The Journal of biological chemistry*  
430 **291**, 3496-3507, doi:10.1074/jbc.M115.672873 (2016).
- 431 10 Matheoud, D. *et al.* Leishmania evades host immunity by inhibiting antigen cross-  
432 presentation through direct cleavage of the SNARE VAMP8. *Cell host & microbe* **14**, 15-  
433 25, doi:10.1016/j.chom.2013.06.003 (2013).
- 434 11 Reverte, M. *et al.* The antioxidant response favors Leishmania parasites survival, limits  
435 inflammation and reprograms the host cell metabolism. *PLoS pathogens* **17**, e1009422,  
436 doi:10.1371/journal.ppat.1009422 (2021).
- 437 12 Matte, C. & Descoteaux, A. Leishmania donovani amastigotes impair gamma interferon-  
438 induced STAT1alpha nuclear translocation by blocking the interaction between  
439 STAT1alpha and importin-alpha5. *Infection and immunity* **78**, 3736-3743,  
440 doi:10.1128/IAI.00046-10 (2010).
- 441 13 Phillips, R. *et al.* Innate killing of Leishmania donovani by macrophages of the splenic  
442 marginal zone requires IRF-7. *PLoS pathogens* **6**, e1000813,  
443 doi:10.1371/journal.ppat.1000813 (2010).
- 444 14 Saha, S. *et al.* Leishmania donovani Exploits Macrophage Heme Oxygenase-1 To  
445 Neutralize Oxidative Burst and TLR Signaling-Dependent Host Defense. *J Immunol* **202**,  
446 827-840, doi:10.4049/jimmunol.1800958 (2019).
- 447 15 Saha, S., Roy, S., Dutta, A., Jana, K. & Ukil, A. Leishmania donovani Targets Host  
448 Transcription Factor NRF2 To Activate Antioxidant Enzyme HO-1 and Transcriptional  
449 Repressor ATF3 for Establishing Infection. *Infection and immunity* **89**, e0076420,  
450 doi:10.1128/IAI.00764-20 (2021).

- 451 16 Espitia, C. M. *et al.* Transcriptional profiling of the spleen in progressive visceral  
452 leishmaniasis reveals mixed expression of type 1 and type 2 cytokine-responsive genes.  
453 *BMC immunology* **15**, 38, doi:10.1186/s12865-014-0038-z (2014).
- 454 17 Gregory, D. J., Sladek, R., Olivier, M. & Matlashewski, G. Comparison of the effects of  
455 *Leishmania major* or *Leishmania donovani* infection on macrophage gene expression.  
456 *Infection and immunity* **76**, 1186-1192, doi:10.1128/IAI.01320-07 (2008).
- 457 18 Kong, F. *et al.* Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals  
458 a Broad Splenic Inflammatory Environment that Conditions Macrophages toward a  
459 Disease-Promoting Phenotype. *PLoS Pathogens* **13**, e1006165,  
460 doi:10.1371/journal.ppat.1006165 (2017).
- 461 19 Morimoto, A. *et al.* Hemophagocytosis induced by *Leishmania donovani* infection is  
462 beneficial to parasite survival within macrophages. *PLoS Neglected Tropical Diseases* **13**,  
463 e0007816, doi:10.1371/journal.pntd.0007816 (2019).
- 464 20 Shadab, M. *et al.* RNA-Seq Revealed Expression of Many Novel Genes Associated With  
465 *Leishmania donovani* Persistence and Clearance in the Host Macrophage. *Frontiers in*  
466 *Cellular and Infection Microbiology* **9**, 17, doi:10.3389/fcimb.2019.00017 (2019).
- 467 21 Chaussabel, D. *et al.* Unique gene expression profiles of human macrophages and dendritic  
468 cells to phylogenetically distinct parasites. *Blood* **102**, 672-681, doi:10.1182/blood-2002-  
469 10-3232 (2003).
- 470 22 Medina-Colorado, A. A. *et al.* Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis  
471 Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function  
472 through Inhibitory Receptor Expression. *PloS One* **12**, e0169496,  
473 doi:10.1371/journal.pone.0169496 (2017).

- 474 23 Forestier, C. L., Machu, C., Loussert, C., Pescher, P. & Spath, G. F. Imaging host cell-  
475 Leishmania interaction dynamics implicates parasite motility, lysosome recruitment, and  
476 host cell wounding in the infection process. *Cell Host & Microbe* **9**, 319-330,  
477 doi:10.1016/j.chom.2011.03.011 (2011).
- 478 24 Smirlis, D. *et al.* SILAC-based quantitative proteomics reveals pleiotropic, phenotypic  
479 modulation in primary murine macrophages infected with the protozoan pathogen  
480 *Leishmania donovani*. *Journal of Proteomics* **213**, 103617,  
481 doi:10.1016/j.jprot.2019.103617 (2020).
- 482 25 Rendra, E. *et al.* Reactive oxygen species (ROS) in macrophage activation and function in  
483 diabetes. *Immunobiology* **224**, 242-253, doi:10.1016/j.imbio.2018.11.010 (2019).
- 484 26 Slupphaug, G., Kavli, B. & Krokan, H. E. The interacting pathways for prevention and  
485 repair of oxidative DNA damage. *Mutation Research* **531**, 231-251,  
486 doi:10.1016/j.mrfmmm.2003.06.002 (2003).
- 487 27 Singh, A. K. *et al.* Proteomic-based approach to gain insight into reprogramming of THP-  
488 1 cells exposed to *Leishmania donovani* over an early temporal window. *Infection and*  
489 *Immunity* **83**, 1853-1868, doi:10.1128/IAI.02833-14 (2015).
- 490 28 Pereira-Lopes, S. *et al.* NBS1 is required for macrophage homeostasis and functional  
491 activity in mice. *Blood* **126**, 2502-2510, doi:10.1182/blood-2015-04-637371 (2015).
- 492 29 Lopez-Sanz, L. *et al.* SOCS1-targeted therapy ameliorates renal and vascular oxidative  
493 stress in diabetes via STAT1 and PI3K inhibition. *Laboratory Investigation* **98**, 1276-  
494 1290, doi:10.1038/s41374-018-0043-6 (2018).

- 495 30 Vomund, S., Schafer, A., Parnham, M. J., Brune, B. & von Knethen, A. Nrf2, the Master  
496 Regulator of Anti-Oxidative Responses. *International Journal of Molecular Sciences* **18**,  
497 doi:10.3390/ijms18122772 (2017).
- 498 31 Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and Function of the PD-L1  
499 Checkpoint. *Immunity* **48**, 434-452, doi:10.1016/j.immuni.2018.03.014 (2018).
- 500 32 Wei, H. *et al.* Suppression of interferon lambda signaling by SOCS-1 results in their  
501 excessive production during influenza virus infection. *PLoS Pathogens* **10**, e1003845,  
502 doi:10.1371/journal.ppat.1003845 (2014).
- 503 33 Srivastav, S. *et al.* Leishmania donovani prevents oxidative burst-mediated apoptosis of  
504 host macrophages through selective induction of suppressors of cytokine signaling (SOCS)  
505 proteins. *The Journal of Biological Chemistry* **289**, 1092-1105,  
506 doi:10.1074/jbc.M113.496323 (2014).
- 507 34 Cortez, M. *et al.* Leishmania promotes its own virulence by inducing expression of the host  
508 immune inhibitory ligand CD200. *Cell Host & Microbe* **9**, 463-471,  
509 doi:10.1016/j.chom.2011.04.014 (2011).
- 510 35 Sauter, I. P. *et al.* TLR9/MyD88/TRIF signaling activates host immune inhibitory CD200  
511 in Leishmania infection. *JCI insight* **4**, doi:10.1172/jci.insight.126207 (2019).
- 512 36 Rawat, A. K. *et al.* The CD200-CD200R cross-talk helps Leishmania donovani to down  
513 regulate macrophage and CD4(+)CD44(+) T cells effector functions in an NFkappaB  
514 independent manner. *International Journal of Biological Macromolecules* **151**, 394-401,  
515 doi:10.1016/j.ijbiomac.2020.02.189 (2020).

516 37 Beattie, L. *et al.* Interferon regulatory factor 7 contributes to the control of *Leishmania*  
517 *donovani* in the mouse liver. *Infection and Immunity* **79**, 1057-1066,  
518 doi:10.1128/IAI.00633-10 (2011).

519 38 Chaparro, V. *et al.* Translational profiling of macrophages infected with *Leishmania*  
520 *donovani* identifies mTOR- and eIF4A-sensitive immune-related transcripts. *PLoS*  
521 *Pathogens* **16**, e1008291, doi:10.1371/journal.ppat.1008291 (2020).

522 39 Leroux, L. P. *et al.* The Protozoan Parasite *Toxoplasma gondii* Selectively Reprograms the  
523 Host Cell Translatome. *Infection and Immunity* **86**, doi:10.1128/IAI.00244-18 (2018).

524 40 Atayde, V. D. *et al.* Exploitation of the *Leishmania* exosomal pathway by *Leishmania* RNA  
525 virus 1. *Nature Microbiology* **4**, 714-723, doi:10.1038/s41564-018-0352-y (2019).

526 41 Ramskold, D., Wang, E. T., Burge, C. B. & Sandberg, R. An abundance of ubiquitously  
527 expressed genes revealed by tissue transcriptome sequence data. *PLoS Computational*  
528 *Biology* **5**, e1000598, doi:10.1371/journal.pcbi.1000598 (2009).


529 42 Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory  
530 requirements. *Nature Methods* **12**, 357-360, doi:10.1038/nmeth.3317 (2015).

531 43 Oertlin, C. *et al.* Generally applicable transcriptome-wide analysis of translation using  
532 anota2seq. *Nucleic Acids Research* **47**, e70, doi:10.1093/nar/gkz223 (2019).

533 44 Mi, H. *et al.* PANTHER version 11: expanded annotation data from Gene Ontology and  
534 Reactome pathways, and data analysis tool enhancements. *Nucleic Acids Research* **45**,  
535 D183-D189, doi:10.1093/nar/gkw1138 (2017).


536 45 Kramer, A., Green, J., Pollard, J., Jr. & Tugendreich, S. Causal analysis approaches in  
537 Ingenuity Pathway Analysis. *Bioinformatics* **30**, 523-530,  
538 doi:10.1093/bioinformatics/btt703 (2014).

# Figures




**Figure 1**

*L. donovani* infection leads to transcriptome-wide changes in macrophage mRNA abundance. (A) Strategy to identify cytosolic mRNAs that are regulated in *L. donovani* amastigote (AMA)- or promastigote (PRO)-infected BMDMs. RNAseq experiments were carried out in three to five biological replicates per condition. (B) Cytosolic mRNA datasets of BMDMs infected or not with *L. donovani* AMA or PRO were projected on the first two components of a principal component analysis. (C) Scatter plots of gene expression as RPKM (log<sub>2</sub>) values for total cytosolic mRNA. Differentially regulated transcripts are indicated in red (Upregulated) or blue (downregulated). Unchanged mRNAs are shown in grey.




**Figure 2**

Selective changes in mRNA abundance predict amastigote-specific modulation of key biological processes in macrophages during *L. donovani* infection. (A) FDR values ( $-\log_{10}$ ) for selected GO term enriched categories of differentially up- or downregulated mRNAs upon *L. donovani* AMA infection. (B) Changes in mRNA abundance for selected genes in enriched GO terms. Analyses were carried out on data generated from at least three biological replicates.



**Figure 3**


Selective changes in mRNA abundance predict promastigote-specific modulation of key biological processes in macrophages during *L. donovani* infection. (A) FDR values ( $-\log_{10}$ ) for selected GO term enriched categories of differentially up- or downregulated mRNAs upon *L. donovani* PRO infection. (B) Changes in mRNA abundance for selected genes in enriched GO terms. Analyses were carried out on data generated from at least three biological replicates.



**Figure 4**

Parasite stage-driven changes in macrophage mRNA abundance during *L. donovani* infection. (A) Scatter plot of gene expression as RPKM (log<sub>2</sub>) values for total mRNA between PRO and AMA datasets. Differentially regulated transcripts are indicated in red (Upregulated) or blue (downregulated). Unchanged mRNAs are shown in grey. (B) Category distribution of transcripts differentially regulated in macrophages upon *L. donovani* PRO versus AMA infection. (C) Heatmaps of selected transcripts differentially regulated

only by amastigotes (left panel), promastigotes (center panel) or both (right panel). Manually curated ontology groups are shown for stage-specific regulated transcripts (left and middle panels). Analyses were carried out on data generated from at least three biological replicates.



**Figure 5**

Ingenuity® Pathway Analysis predicts parasite stage-specific modulation of transcriptional regulators in macrophages infected *L. donovani*. (A) Activation score (Z) of transcriptional regulators predicted to be involved in the changes of mRNA abundance in macrophages upon *L. donovani* AMA and PRO infection. \*Common upstream regulators identified in PRO, AMA datasets by IPA®. (B) Percentage distribution of upregulated mRNAs associated with upstream transcriptional regulators predicted to be activated in macrophages upon *L. donovani* AMA and PRO infection. Total number of genes regulated by each transcription factor are shown in brackets. Analyses were carried out on data generated from at least three biological replicates.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [ChaparroetalTableS1.xlsx](#)
- [ChaparroetalTableS2.xlsx](#)
- [ChaparroetalTableS3.xlsx](#)